Jonathan M. Pratt became QIAGEN N.V.’s chief executive officer on September 1, 2026, replacing Thierry Bernard, who also left the Managing Board. Investors retain the company’s reaffirmed third-quarter and full-year 2026 outlook, while QIAGEN continues a strategic review and plans to propose Pratt as a Managing Director for Shareholder approval.

Key Highlights

  • Thierry Bernard stepped down from QIAGEN’s Managing Board when Pratt assumed the CEO position.
  • Jonathan M. Pratt became QIAGEN’s chief executive officer effective September 1, 2026.
  • Thierry Bernard stepped down as CEO and from the Managing Board on September 1, 2026.
  • QIAGEN reaffirmed its third-quarter and full-year 2026 outlook as its strategic review continues.

QIAGEN N.V. (NYSE: QGEN) appointed Jonathan M. Pratt as chief executive officer effective September 1, 2026, succeeding Thierry Bernard. Bernard also stepped down from the Managing Board on that date, while QIAGEN reaffirmed its third-quarter and full-year 2026 outlook.

Pratt Takes Over

as CEO Pratt brings more than 25 years of Leadership experience across life sciences, laboratory technologies and healthcare. His previous roles included chief executive officer of Filtration Group, senior vice president of the Waters Division at Waters Corporation (NYSE: WAT), and president of Beckman Coulter Life Sciences. He also held senior leadership positions at Pall Corporation. Bernard will support the leadership handover through the transition.

Outlook Reaffirmed

as Strategic Review Continues QIAGEN reaffirmed its outlook for the third quarter and full year of 2026. The company said it remains focused on profitable growth, operating efficiency and directing Capital toward the highest-return opportunities. The Supervisory Board is continuing its strategic review with independent financial and legal advisers.